Loading the company…
Loading the company…
㈜코박메드
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2010. Industry: Medical & Precision Devices. Revenue for 2025 was ₩43.7bn. It has 229 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2018-01-23 · latest registration 2018-08-07 · newest first
본 고안은 확장부와 니들 간의 결합력과 고정력이 우수한 캐뉼라에 관한 것으로, 더욱 상세하게는 니들은 소정길이를 갖는 원통 형상으로 이루어지되 외면에 상기 확장부 내부로 삽입되어 접착시에 상기 확장부와의 마찰력에 의해 결합력을 높일 수 있도록 형성된 결합수단을 포함하되, 상기 결합수단은 상기 확장부에 삽입되는 상기 니들의 삽입영역에 소정깊이를 갖도록 레이저가공에 의해 상기 니들 외면을 녹여 형성된 홈부, 상기 홈부와 이어지도록 상기 니들 외측 방향으로 돌출된 돌출부를 포함하는 것을 특징으로 한다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 34.5 | 43.7 |
| Cost of sales | 26.0 | 31.3 |
| Gross profit (loss) | 8.5 | 12.5 |
| Selling, general and administrative expenses | 3.8 | 5.4 |
| Operating income (loss) | 4.6 | 7.0 |
| Non-operating income | 4.8 | 2.9 |
| Other gains | 0.0 | 0.0 |
| Finance income | 0.9 | 0.9 |
| Other | 3.9 | 2.0 |
| Non-operating expenses | 1.1 | 2.6 |
| Other losses | 0.0 | 0.1 |
| Finance costs | — | 0.0 |
| Other | 1.1 | 2.5 |
| Profit (loss) before tax | 8.3 | 7.4 |
| Income tax expense | 1.6 | 2.3 |
| Net income (loss) | 6.7 | 5.1 |
Revenue ₩43.7bn, up 26.6% YoY.
Operating margin 16.1% (prior 13.5%).
Net income ₩5.1bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06